Pay with

USD

Supports Visa, Mastercard, SEPA & more

Flexible trading, zero fees

Use your crypto for payments worldwide

Basic

Trade crypto freely

Magnify your profit with leverage

Convert & Auto-Invest

Trade any size with no fees and no slippage

Get exposure to leveraged positions simply

Pre-Market Trading

Trade new tokens before listing

Advanced

Trade on-chain with Gate Wallet

Smart access to new on-chain tokens

Smart strategies with automated trading

Follow expert trading strategies

CrossEx Trading

One margin balance, shared across platforms

Access hundreds of perpetual contracts

One platform for global traditional assets

Trade European-style vanilla options

Unified Account

Maximize your capital efficiency

Introduction to Futures Trading

Learn the basics of futures trading

Join events to earn rewards

Use virtual funds to practice risk-free trading

Launch

Collect candies to earn airdrops

Quick staking, earn potential new tokens

Hold GT and get massive airdrops for free

Unlock full access to global stock IPOs

Trade on-chain assets and earn airdrops

Earn futures points and claim airdrop rewards

Investment

Earn interest with idle tokens

Auto-invest on a regular basis

Dual Investment

Profit from market volatility

Earn rewards with flexible staking

Pledge one crypto to borrow another

One-stop lending hub

Premium wealth growth plans

Private Wealth Management

Premium asset allocation

Top-tier quant strategies

Stake cryptos to earn in PoS products

No-liquidation leverage

Mint GUSD for RWA returns

Post, share, and explore crypto trends

Live crypto market analysis

Chat with crypto traders

What is happening in crypto

More

HRMY stock on track for best intraday gains in 18 months — what did Mizuho analysts say?

2026-04-21 20:14:22

Abstract generation in progress

Harmony Biosciences Holdings (HRMY) experienced its best intraday stock gains in 18 months following an upgraded rating from Mizuho analysts. The analysts reiterated a Buy rating and increased their price target to $60, citing confidence in the company’s Q1 sales of Wakix and potential for growth with its narcolepsy and Prader-Willi syndrome drug.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
299.02K Popularity
#
Gate13thAnniversaryLive
872.31K Popularity
#
BitcoinBouncesBack
173.16K Popularity
#
USIranTalksProgress
879.23K Popularity
#
HKUnveilsNewCryptoRules
274.66K Popularity

Pin